Skip to main content

Table 2 Predictive factors for tumor response

From: Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer

Variable Complete or Partial Response Stabilization or progression p value (Chi Square) Binary logistic regressionb p-value
Gender
 Male (n = 35) 60% 40% 0.4 NI  
 Female (n = 11) 72.7% 27.3%    
Histology
 Squamous (n = 22) 59.1% 40.9% 0.6 NI  
 Non squamous (n = 24) 66.7% 33.3%    
Age
  < 66 years (n = 23) 69.6% 30.4% 0.3 NI  
  ≥ 66 years (n = 23) 56.5% 43.5%    
Dose of reirradiation
 BED ≤130 Gy (n = 18) 50% 50% 0.14 NI  
 BED > 130 Gy (n = 28) 71.4% 28.6%    
 BEDmin ≤50 Gy (n = 22) 54.5% 45.5% 0.3 NI  
 BEDmin > 50 Gy (n = 23) 69.6% 30.4%    
Tumor size
  ≥ 33 mm (n = 21) 42.9% 57.1% 0.008 1 0.04
  < 33 mm (n = 22) 81.8% 18.2%   OR = 0.21  
 Missing value (n = 3)     [0.04–0.93]  
GTV Volume
  ≥ 13 mL (n = 22) 33.3% 76.5% 0.005 NI  
  < 13 mL (n = 22) 66.7% 23.5%    
 Missing value (n = 2)      
SABR duration
  ≥ 6 days (n = 25) 64% 36% 0.8 NI  
  < 6 days (n = 21) 61.9% 38.1%    
Number of fractions
  > 3 (n = 30) 60% 40% 0.5 NI  
  ≤ 3 (n = 16) 68.8% 31.2%    
Dose per fraction
  > 12 (n = 23) 69.6% 30.4% 0.3 NI  
  ≤ 12 (n = 16) 56.5% 43.5%    
Performans Status ECOGa
 0 (n = 27) 70.4% 29.6% 0.9 NI  
 1 (n = 11) 72.7% 27.3%    
 Missing value (n = 8)      
Location of relapse
 Central (n = 24) 50% 50% 0.06 NI  
 Peripheral (n = 22) 77.3% 22.7%    
Primary stage (at first irradiation)
 IIIA (n = 21) 61.9% 38.1% 0.9 NI  
 IIIB (n = 25) 64% 36%    
In-field relapse
 Yes (n = 29) 48.3% 51.7% 0.03 1 0.14
 No (n = 17) 82.4% 17.6%   OR = 0.26 [0.04–1.6]  
In-field relapse and central tumors
 Yes (n = 19) 35.3% 64.7% 0.01 NIc  
 No (n = 26) 72.4% 27.6%    
GTV coverage
  < 95% (n = 22) 50% 50% 0.07 NI  
  ≥ 95% (n = 24) 75% 25%    
PTV coverage
  < 90% (n = 23) 47.8% 52.2% p = 0.03 1 0.11
  ≥ 90% (n = 23) 78.3% 21.7%   OR = 3.2 [0.74–13.8]  
  1. aAt time of stereotactic ablative radiotherapy; ECOG = Eastern Cooperative Oncology Group
  2. bComplete-Partial response versus stabilization-progression
  3. cIf “in-field relapse and central tumors” is included in multivariate model instead of “in-field relapse”: p-value for “in-field relapse and central tumors” = 0.08 (0.03 for tumor size and 0.15 for PTV coverage)